Related Experiment Video

Updated: Feb 19, 2026

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.4K

SPARC inhibits breast cancer bone metastasis and may be a clinical therapeutic target

Jingjing Ma1, Sheng Gao1, Xiju Xie2

  • 1State Key Laboratory of Reproductive Medicine, Department of Breast Surgery, Nanjing Maternity and Child Health Care Hospital Affiliated to Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China.

Oncology Letters
|November 9, 2017
PubMed

Insights

Secreted protein acidic and rich in cysteine (SPARC) plays a key role in breast cancer bone metastasis. This study found SPARC inhibits cancer cell invasion and osteoclast activation, suggesting it as a therapeutic target.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Breast cancer is a prevalent malignancy globally, with bone metastasis being a significant challenge.
  • Understanding the molecular mechanisms driving breast cancer bone metastasis is crucial for developing effective treatments.

Purpose of the Study:

  • To investigate the role of secreted protein acidic and rich in cysteine (SPARC) in the molecular mechanisms of breast cancer metastasis to bone.
  • To evaluate SPARC as a potential therapeutic target for breast cancer bone metastasis.

Main Methods:

  • Immunohistochemistry to assess SPARC expression in primary tumors and bone metastases.
  • Western blotting and RT-qPCR to determine SPARC levels in breast cancer cell lines.
  • Transwell assays for cell invasion and osteoblast differentiation assays for mesenchymal stem cell differentiation.

Main Results:

  • Decreased stromal SPARC expression correlated with breast cancer to bone metastasis.
  • SPARC was found to inhibit breast cancer cell migration and invasion.
  • SPARC suppressed osteoclast activation within the tumor microenvironment.

Conclusions:

  • SPARC plays a critical role in regulating breast cancer bone metastasis.
  • SPARC's inhibitory effects on cancer cell invasion and osteoclast activity highlight its potential as a therapeutic target.
Keywords:
bone metastasisbreast cancersecreted protein acidic and rich in cysteine

More Related Videos

Intra-iliac Artery Injection for Efficient and Selective Modeling of Microscopic Bone Metastasis07:00

Intra-iliac Artery Injection for Efficient and Selective Modeling of Microscopic Bone Metastasis

Published on: September 26, 2016

17.5K
Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

12.7K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K